The protein tyrosine phosphatase RPTPζ/phosphacan is critical for perineuronal net structure

Geoffrey J. Eill, Ashis Sinha, Markus Morawski, Mariano S. Viapiano, and Russell T. Matthews

Perineuronal nets (PNNs) are conspicuous neuron-specific substructures within the extracellular matrix of the central nervous system that have generated an explosion of interest over the last decade. These reticulated structures appear to surround synapses on the cell bodies of a subset of the neurons in the central nervous system and play key roles in both developmental and adult-brain plasticity. Despite the interest in these structures and compelling demonstrations of their importance in regulating plasticity, their precise functional mechanisms remain elusive. The limited mechanistic understanding of PNNs is primarily because of an incomplete knowledge of their molecular composition and structure and a failure to identify PNN-specific targets. Thus, it has been challenging to precisely manipulate PNNs to rigorously investigate their function. Here, using mouse models and neuronal cultures, we demonstrate a role of receptor protein tyrosine phosphatase zeta (RPTPζ) in PNN structure. We found that in the absence of RPTPζ, the reticular structure of PNNs is lost and phenocopies the PNN structural abnormalities observed in tenasin-R knockout brains. Furthermore, we biochemically analyzed the contribution of RPTPζ to PNN formation and structure, which enabled us to generate a more detailed model for PNNs. We provide evidence for two distinct kinds of interactions of PNN components with the neuronal surface, one dependent on RPTPζ and the other requiring the glycosaminoglycan hyaluronan. We propose that these findings offer important insight into PNN structure and lay important groundwork for future strategies to specifically disrupt PNNs to precisely dissect their function.

Studies over the past two decades have identified the important and perhaps fundamental role for the neural extracellular matrix (ECM) in regulating neuronal plasticity in the central nervous system (CNS). For example, manipulation of the neural ECM disrupts developmental ocular dominance plasticity in the primary visual cortex and modulates learning and memory in multiple regions within the brain (1–3). Indeed, alterations and/or disruptions of the neural ECM are associated with a number of neuropsychiatric disorders and neurodegenerative diseases (4–8). Importantly, these studies primarily attribute these functions to a unique and enigmatic neural ECM substructure called the perineuronal net (PNN).

PNNs are conspicuous reticular ECM formations that ensheathe limited but specific subsets of neurons in the CNS (9, 10). These highly aggregated ECM structures surround the cell body and proximal neurites of ensheathed neurons but appear to be excluded from sites of synaptic contact thereby giving them a lattice-like or net-like appearance. Early work noted that expression of PNNs in primary sensory cortices, such as visual and somatosensory cortex, is activity dependent and that the timing of their appearance is consistent with closure of developmental critical periods such as the critical period for ocular dominance plasticity (11, 12). Furthermore, in the cortex, PNNs are particularly enriched surrounding parvalbumin-expressing interneurons, which are known to be key regulators of developmental plasticity. Therefore, it is hypothesized that PNNs may be important regulators of developmental plasticity in the developing cortex.

Previous work showed that PNNs are particularly enriched in the glycosaminoglycan hyaluronan (HA) and hyaluronan-binding chondroitin sulfate proteoglycans (CSPGs). The presence of highly aggregated CSPGs in PNNs has received particular attention because CSPGs are notoriously inhibitory molecules in the CNS and a major barrier to regeneration in the injured nervous system (13–15). Therefore, the appearance of CSPG-enriched structure surrounding synapses coincident with closure of the period of heightened developmental plasticity led to the hypothesis that these structures likely inhibit synaptic plasticity. Consistent with this hypothesis more recent studies demonstrated that, indeed, disruption of the neural ECM and PNNs in the visual cortex restores juvenile ocular dominance.

The abbreviations used are: ECM, extracellular matrix; CNS, central nervous system; PNN, perineuronal net; HA, hyaluronan; CSPG, chondroitin sulfate proteoglycan; ChABC, chondroitinase ABC; RPTPζ, receptor protein tyrosine phosphatase zeta; IHC, immunohistochemistry; WFA, Wisteria floribunda agglutinin; PFA, paraformaldehyde; ANOVA, analysis of variance; DIV, day in vitro; PND, postnatal day; E, embryonic day; Tnr, tenascin-R.
RPTPζ is critical for PNNs

plasticity in mature rodent brain (1). Importantly these findings suggest that ECM and PNN disruption alone is sufficient to reopen juvenile plasticity, indicating that these are critical regulators of neural plasticity.

The body of work linking PNNs to developmental plasticity (16–18) is quite compelling, however; an ever-growing list of studies now links PNNs to a vast array of neural functions and pathologies. Of particular interest are prominent roles for PNNs in other forms of plasticity such as learning and memory. An explosion of recent work demonstrated that manipulating the ECM and PNNs in multiple brain regions including the amygdala, hippocampus, cortex, and striatum significantly alters learning and memory (2, 3, 19–22). Although these results are quite striking and exciting for the field, a mechanistic understanding of PNN function has been surprisingly elusive. We still do not understand what the precise function of PNNs is nor how they modulate plasticity. In addition, there are conflicting findings from different labs with PNN manipulations that further highlight the limits of our understanding of this structure (23, 24).

The limited mechanistic understanding of PNN function is derived primarily from an incomplete understanding of its molecular composition and structure and, in turn, the inability to specifically disrupt PNNs without disrupting the surrounding ECM. For example, much of the work identifying roles for PNNs in various forms of plasticity has relied on enzymatic digestion with chondroitinase ABC (ChABC). This treatment impacts PNNs but does not necessarily eliminate the structure, and even disrupts the surrounding ECM (25). Additionally, genetic models disrupting specific PNN components have provided insight into their function, but also typically impact the surrounding neural ECM. Therefore, the goal of this study is to provide a more complete understanding of PNN structure toward the ultimate goal of developing more precise strategies to specifically disrupt PNNs to better study their function.

In this study we detail a novel role for receptor protein tyrosine phosphatase zeta (RPTPζ) in the structure of PNNs. Utilizing mouse models and neuronal cultures, we demonstrate RPTPζ is critical for the proper formation of PNNs. Further analysis using molecular and biochemical techniques shows PNNs are bound to the neuronal surface through two distinct mechanisms, one requiring hyaluronan and the other RPTPζ. Overall, our data provide novel insights into the structure and formation of PNNs to ultimately develop tools to precisely determine PNN function.

Results

PNNs are disrupted in Ptprz1 KO adult mice

A detailed understanding of PNN function has been elusive due in large part to an incomplete understanding of their composition and structure. In this regard the role of RPTPζ in PNNs is intriguing because although it has been localized to PNNs, its role in these structures has never been thoroughly studied. Although virtually all other proteins identified in PNNs are secreted proteins, the full-length isoform of RPTPζ is a large transmembrane protein and thereby could provide a key anchor point for PNNs to the neuronal cell surface. Furthermore, RPTPζ is a phosphatase and could also serve a signaling function in PNNs. Finally, RPTPζ is known to interact with other key PNN components such as Tnr and could provide a key link to the other components in this structure. Therefore, we investigated PNN structure in Ptprz1 KO mice. Of note, the nomenclature surrounding the protein products of the Ptprz1 gene, RPTPζ and phosphacan, in the literature is somewhat confusing. This largely stems from various laboratories isolating the proteoglycan using different monoclonal antibodies. As such RPTPζ is also known by DSD-1, 6B4, 3F8, and RPTPβ. It is now generally accepted that the receptor form be described as RPTPζ, to match its gene Ptprz1 (Ptprz1). Therefore, in this article, we will designate all protein isoforms of the Ptprz1 gene as RPTPζ and specifically name the secreted variant phosphacan where relevant.

Before investigating PNN structure, we confirmed the loss of RPTPζ of our Ptprz1 KO mice through immunostaining using RPTPζ-specific antibody 3F8 in adult cortical sections (Fig. S1A). 3F8 staining was essentially eliminated in the brains of the knockout animals confirming the validity of this model. We subsequently immunostained cortical sections of PND 90 brains with the most well-established markers of PNNs, antibodies directed against aggrecan and the lectin WFA. In WT brains, PNNs had the typical highly organized lattice structure on a subset of neurons in the cortex. However, PNNs in the KO brains appeared altered in structure and less organized than their WT counterparts. Upon closer observation, we noted that although typical PNN staining reveals bridgelike strings interconnecting foci along the neuronal surface that create discrete gaps or holes that give a netlike appearance, these “bridges” seemed largely absent in the KO brains (Fig. 1). Interestingly PNNs in brains from heterozygous mice seemed largely unaffected. In the KO animals, however, instead of the intricate, lattice-like structure as seen in WT, PNN components aggregated on the neuronal surface, creating prominent foci. Despite this disrupted structure, interestingly, PNN areal and cell-specific distribution remained unaffected in Ptprz1 KO mice. In addition, we found this disruption occurred as early as PND 21 (Fig. S1B). From these data, we concluded RPTPζ is necessary for proper formation of PNNs from early in mammalian development through maturity.

To quantify the disrupted PNN phenotype, we analyzed two aspects of PNN staining: PNN intensity and PNN spatial distribution on the neuronal surface. Cortical brain slices were stained with WFA and individual PNN-bearing neurons were imaged and analyzed across the Ptprz1 brains (WT, n = 4 animals, 55 PNNs; Het, n = 3 animals, 26 PNNs; KO, n = 4 animals, 43 PNNs). From our initial observations, we found that disrupted Ptprz1 KO PNNs had large areas devoid of PNN staining, possibly because of component aggregation and collapse of the stringlike interconnections (Fig. 2A). To quantify this observation, we first developed a binary gap analysis as described in “Experimental procedures” (Fig. 2). A binary process converts any image of varying pixel intensity to black and white using an unbiased calculated threshold, making it a useful analysis tool to assess the empty space of an image (Fig. 2B). Of particular interest, the binary image of control PNNs distinctly shows the well-defined gaps and regular lattice-like structure of
PNNs. In Ptprz1 KO mice, however, the gaps are no longer well-defined and PNN staining appears aggregated and discontinuous leading to gaps or large areas of no PNN staining. After calculating the black/white pixel count ratio, we found no significant difference between Ptprz1 WT and Het PNNs (data not shown), therefore the data sets were combined. In Ptprz1 KO PNNs, however, we found a significantly higher black/white pixel count ratio ($p = 1.09 \times 10^{-5}$, Student’s $t$ test), confirming greater areas of no PNN staining (Fig. 2C).

The above method effectively describes the ratio of PNN-containing regions to regions devoid of PNN staining on the surface of neurons between Ptprz1 WT/Het and Ptprz1 KO animals. However, in addition to this, PNN staining from the Ptprz1 KO neurons appears discontinuous and aggregated in contrast to the more regular, continuous staining seen in Ptprz1 WT/Het animals. To quantify this element of PNN structure we developed a PNN peak or node analysis. This method takes into account the difference in spatial distribution and clustering of PNN staining on the cell surface between the different groups. As before we utilized WFA as a marker for PNNs. We determined the sharpness of PNN peaks seen on the neuronal surface using the local maxima function in ImageJ (Fig. 2, D and E). The more continuous and regular WFA staining of the Ptprz1 WT/Het group resulted in significantly higher number of nodes or peaks in this genotype. The aggregated staining of the Ptprz1 KO PNNs led to detection of significantly fewer nodes ($p = 0.0009$, Student’s $t$ test), which also appeared more isolated than in Ptprz1 WT/Het animals (Fig. 2F). The average prominence of PNN nodes over their surrounding space in the Ptprz1 KO PNNs was also significantly higher compared with Ptprz1 WT/Het PNNs ($p = 0.014$, Student’s $t$ test) (Fig. 2G). Both these data indicate the regular continuous structure of PNNs in the Ptprz1 WT/Het animals and the broken discontinuous PNN staining seen in Ptprz1 KO cells. The increase in the average prominence levels of WFA peaks in the Ptprz1 KO PNNs further points to the isolated nature of PNN nodes and the loss of connections between them in the Ptprz1 KO animals.

ECM components remain bound to disrupted PNN structures in Ptprz1 KO mice

Although our data indicate that proper PNN structure is disrupted in Ptprz1 KO mice, the impact of RPTPζ on the other known PNN components remains unclear. To further define how RPTPζ contributes to the underlying structure of PNNs, we stained cortical sections of adult Ptprz1 mice with PNN markers WFA, aggrecan, HAPLN1, neurocan, brevican, and Tnr, and further quantified for fluorescent intensity (Fig. 3, A). Although staining with all components showed the same aggregate PNN structure found with aggrecan and WFA, all ECM components, including Tnr, remained bound to PNNs in Ptprz1 KO mice. Quantifying the various PNN components, and accounting for sex, we found no significant ECM intensity difference between Ptprz1 WT ($n = 9; 3$ males, $6$ females) and Ptprz1 Het ($n = 12; 6$ males and $6$ females) mice for most of the PNN components. When compared with Ptprz1 KO mice ($n = 14; 4$ males, $10$ females), we only found significant losses in WFA ($p = 6.53 \times 10^{-5}$, Student’s $t$ test) and aggrecan ($p = 0.01$) whereas no significant losses were seen for all other PNN components analyzed.

Expression of aggrecan and hyaluronic and proteoglycan link protein 1 (HAPLN1) in the cortex of Ptprz1 mice was analyzed via Western blot analysis ($n = 3$ per genotype) (Fig. 3B). Similar to IHC results, aggrecan protein levels in the cortex were significantly reduced in Ptprz1 KO mice ($p = 0.03$, Student’s $t$ test), while HAPLN1 protein levels remained unchanged ($p = 0.64$). To ensure aggrecan loss did not occur at the transcription level, we performed an RT-PCR analysis and found no significant changes in gene expression across all Ptprz1 (data not shown). From these analyses, we conclude that although important for proper structural formation, the loss of RPTPζ does not affect the overall localization of ECM components to the PNN surface.

The PNN disruption in Ptprz1 KO mice phenocopies the PNN disruption in tenascin-R KO mice

We next sought to determine a mechanism in which RPTPζ anchors PNNs to the surface. We noted that the PNN phenotype we observed in the Ptprz1 KO brains looked remarkably similar to the phenotype found previously in Tnr KO brains (26, 27). Additionally, Tnr is of particular interest because it is a high-affinity binding partner of RPTPζ (28–30). To confirm our observations, we obtained PFA-fixed PND 90 adult brains of Tnr WT and Tnr KO mice and directly compared the PNN phenotype to Ptprz1 KO mice (Fig. 4). Staining with WFA and aggrecan antibody, PNNs in Tnr WT resembled a typical lattice-like structure as observed with Ptprz1 WT/Het PNNs. The lattice-like structure of controls was completely absent and replaced by areas of aggregation. More importantly, these phe-
RPTPζ/phosphacan is critical for PNNs

notypes were indistinguishable from PNNs in Ptprz1 KO mice. From these data, we concluded RPTPζ likely interacts with Tnr to mediate PNN structure.

PNN component aggrecan is immobilized on the cell surface by a distinct HA- and EDTA-sensitive interaction

Previous work has identified and demonstrated the importance of Tnr, HAPLN1, and the lectican CSPGs, aggrecan, neurocan, and brevican, in the proper formation of PNNs (23, 26, 27, 30–41). We have found PNNs to be disrupted in Ptprz1 KO mice. However, the exact mechanism by which these components bind together to form PNNs is not clear. To better understand the mechanism of binding of PNN components we established a biochemical release assay to measure binding of aggrecan to the neuronal cell surface. Aggrecan is the best PNN component for this analysis because it is the most PNN-specific component and recently has been shown to be perhaps the key CSPG in PNN formation (24). Our finding of the potential interaction between RPTPζ and Tnr in PNN structure led to our hypothesis that we should be able to disrupt this element of PNN structure by chelating calcium. The interaction between RPTPζ and Tnr is Ca2+ dependent and, subsequently, the interaction of Tnr with aggrecan also depends on Ca2+. Therefore, we reasoned that treatment with EDTA would disrupt this entire complex and if this complex were involved in PNN cell-surface binding, would enhance the release of aggrecan. In addition, current models of PNN structure suggest that aggrecan is immobilized to the cell surface by interacting with the PNN backbone made up of the glycosaminoglycan HA (32, 40, 42). Therefore, we reasoned digestion of HA should also increase the release of aggrecan. If both mechanisms are independently involved in the binding of aggrecan to the neuronal membrane then we hypothesized that in the Ptprz1 and Tnr KO brain, aggrecan release would depend only on HA. To test this

Figure 2. PNNs from Ptprz1 WT or Ptprz1 Het mice are distinct from those derived from Ptprz1 KO animals. PNNs from PND 90 adult WT, Het, and KO mice were stained with WFA and quantified. WT and Het animals showed no statistically significant difference in any of the following analyses and were grouped together as WT/Het. A, PNNs from WT/Het appear brighter and show regular meshlike PNN appearance whereas KO PNNs show decreased WFA intensity and a disrupted staining pattern. B, shows a magnified view of the surface of the cells in A converted to binary images. C, KO animals showed significantly higher black/white pixel ratio, indicating an increased area devoid of PNN staining (p = 1.09 × 10−5, two-tailed Student’s t test, S.D. for error bars). D, representative image of WT/Het and KO PNNs for PNN peak/node analysis at varying prominence levels. Yellow color dots represent nodes/peaks of highest prominence (more isolated) followed by green, blue, and black. E, representative surface intensity profile of PNNs from WT/Het and KO animals. WT/Het PNNs show greater number of peaks as compared with KO PNNs. KO PNNs also appear more isolated with sharper peaks. F, WT/Het PNNs showed significantly higher number of peaks as compared with Ptprz1 KO PNNs (p = 0.0009, two-tailed Student’s t test, S.D. for error bars). G, the average isolation index of PNN peaks (represented here as the mean prominence level of all the peaks) was significantly higher in KO PNNs as compared with WT/Het PNNs (p = 0.014, two-tailed Student’s t test, S.D. for error bars) indicating the fewer and more sharp peaks in case of the KO animals. Binary image analysis and PNN peak/node analysis were carried out on WT (n = 4 animals, 55 PNNs), Het (n = 3 animals, 26 PNNs), KO (n = 4 animals, 43 PNNs). Images in (B) are 5 μm × 5 μm. Scale bar, 5 μm.
hypothesis, we isolated membranes from adult mouse brains and assessed the release of aggrecan by HA digestion in WT, Ptprz1 KO, and Tnr KO tissue (Fig. 5). We found that there is very little release of aggrecan from brains of WT mice (15 ± 9%). In contrast, there was significant difference in release of aggrecan among the groups (one-way ANOVA F(2,7) = 14.94, p = 0.003). Both Ptprz1 KO brains (42 ± 4%, p = 0.0340) and Tnr KO brains (58 ± 13%, p = 0.0024) showed greater release as compared with WT. Interestingly, the vast majority of aggrecan was released from WT brains in our ChABC in conjunction with EDTA treatment assays (82 ± 7%). Ptprz1 KO brains (87 ± 19%) and Tnr KO (80 ± 27%) brains also showed an increase and similar levels of aggrecan release to WT brains when treated with both ChABC and EDTA.

These data indicate that in WT mice aggrecan is immobilized on the cell surface by a dual interaction which is sensitive to HA digestion and EDTA, respectively. Attachment of aggrecan in either Ptprz1 KO or Tnr KO brains is compromised and the EDTA-sensitive mechanism of aggrecan binding is lost. These data along with the fact that aggrecan is similarly solubilized in our biochemical release assay from Ptprz1 KO and Tnr KO mice suggest that these two proteins are involved in aggregating this CSPG to the cell surface via the same mechanism. We next proceeded to further test the role of RPTPζ and Tnr in immobilizing aggrecan to the cell surface.

Tnr and RPTPζ are both required to bind aggrecan to the cell surface

The role of Tnr in proper formation of PNNs is well-known and has been demonstrated in a number of systems, including brain slices, organotypic cultures, and dissociated neurons from Tnr KO mice (26, 37, 38). Here we show RPTPζ disruption phenocopies the PNN structural deficit found in the Tnr KOs. Because RPTPζ and Tnr are high-affinity ligands for each other, we hypothesize these proteins interact in mediating PNN structure. To more thoroughly characterize the binding of aggrecan to the cell surface through RPTPζ and Tnr, we endeavored to recapitulate the effect in HEK293 cells, a cell line that does not
form PNNs endogenously (Fig. 6). We found that adding aggrecan alone or aggrecan and Tnr does not result in binding the CSPG to the cell surface (Fig. 6, A–C). This is not completely surprising as Tnr is a secreted glycoprotein and does not contain any transmembrane domains to anchor it to the cell surface. Thus, its primary role is likely involved in the crosslinking PNN components to the cell surface and not to immobilize them on the cell. We then tested whether the binding of Tnr to the cell surface can be mediated by RPTPζ by expressing a construct containing the Tnr binding domain of RPTPζ in the HEK293 cells (Fig. 6, D–F). We found that in the presence of Tnr, cells expressing RPTPζ formed pericellular aggregates of aggrecan (Fig. 6D). Furthermore, HEK293 cells did not bind aggrecan when only RPTPζ was expressed, but required the presence of Tnr. These results demonstrate that both these two proteins are required to bind aggrecan to the cell surface. Interestingly, adding HA to these cells further enhanced staining and the netlike appearance of the structure highlighting the importance of HA in the aggregating PNN components to the cell surface (Fig. 6F).

**Ptpz1 KO neurons show disrupted PNN distribution and distinct biochemical properties in culture as compared with WT neurons**

Dissociated neuronal cultures present an attractive model to study binding of PNN components to the neuronal surface. This model system allowed us to perform biochemical analysis in live cells. We therefore utilized dissociated neuronal cultures to more thoroughly assess the role of RPTPζ in binding PNN components to the cell surface. Cultures were derived from E16 CD1 WT and Ptpz1 KO mice and were positive for PNN marker aggrecan (Fig. 7, A and E). However, staining in the Ptpz1 KO cells appeared disrupted and reduced in intensity as compared with the WT cultures, indicating the role of RPTPζ...
in binding PNN components to the cell surface. Our previous findings have shown that the interaction of aggrecan with the cell surface is mediated by RPTPζ and Tnr. Further, this interaction depends on two kinds of mechanisms, being sensitive to HA digestion and Ca2+ ions, respectively. To determine the binding mechanism of aggrecan to cell surface and the role of RPTPζ in PNN formation we treated neuronal cultures from WT and Ptprz1 KO mice acutely with ChABC and/or EGTA. There are significant effects of genotype (F(1,16) = 69.57, p < 0.0001) and treatment (F(3,16) = 36.46, p < 0.0001) as well as interaction (F(3,16) = 5.479, p = 0.0088) on aggrecan staining when analyzed by two-way ANOVA. Tukey’s post hoc testing (Fig. 7I) showed that acute treatment with ChABC alone had only a moderate effect on the release of aggrecan from WT cultures (Fig. 7B) (55 ± 2%, p = 0.0042). In contrast, the effect of ChABC treatment was dramatically enhanced in Ptprz1 KO cultures and led to a virtually complete loss of aggrecan staining in these cells (Fig. 7F) (14 ± 3%, p = 0.0202). Further, this effect of ChABC treatment was significantly different between the two genotypes (p = 0.0015). EGTA treatment alone only had a small effect on aggrecan staining in both WT (Fig. 7C) (79 ± 11%, p = 0.3788) and Ptprz1 KO cultures (Fig. 7G) (84 ± 19%, p = 0.9958). Interestingly, the combination of the two treatments, i.e. ChABC in conjunction with EGTA, led to almost complete loss of aggrecan in WT (Fig. 7D) (11 ± 2%, p < 0.0001) as well as Ptprz1 KO cultures (Fig. 7H) (9 ± 2%, p = 0.0137). These findings confirm our previous result and indicate that PNN component aggrecan is immobilized on the cell surface via two interactions, being sensitive to ChABC and a loss of Ca2+ ions, respectively. Further they indicate that the Ca2+ dependent interaction is mediated by RPTPζ and is compromised in the Ptprz1 KO animals.
Phosphacan and tenascin-R cooperate to stabilize PNN components to the neuronal surface

Currently, we have shown that Tnr remains bound to PNNs in Ptprz1 KO mice. If RPTPζ does indeed anchor PNNs through Tnr, we would expect RPTPζ to remain present on PNNs in Tnr KO mice. To test this hypothesis, we stained for RPTPζ on cortical sections of Tnr KO mice (Fig. 8A). Intriguingly RPTPζ, although prominent in Tnr WT, was greatly diminished on Tnr KO PNNs consistent with previous studies (26). This suggests Tnr expression is needed to maintain RPTPζ on the neuronal surface of PNNs. To better understand the molecular composition of PNNs

Figure 8. Phosphacan and Tnr cooperate to stabilize PNN components to the neuronal surface. A, in PND 90 adult cortical sections from Tnr KO mice, RPTPζ (3F8) was largely reduced in PNNs (detected with anti-aggrecaen antibodies) compared with WT mice. Of note, HAPLN1 still persists on PNNs in Tnr KO mice. Scale bar, 10 μm. B, cortical cultures derived from E16 WT and Ptprz1 KO were fixed at DIV 9 and stained with PNN components, aggrecaen, neurocan, and Tnr. We observed a distinct disruption of these components in Ptprz1 KO neuronal cultures when compared with WT. In addition, Tnr expression is largely reduced in Ptprz1 KO neuronal cultures. To determine which Ptprz1 isoform contributes to PNN structure, we purified the soluble form, phosphacan from PND 4 mouse brains through anion exchange chromatography. Purified phosphacan (0.25 μg) was added to Ptprz1 KO neuronal cultures at 3 DIV. Cells were fixed and stained at 9 DIV for PNN components. Intriguingly, exogenous phosphacan seemingly recovered disrupted ECM to resemble WT morphology and expression, suggesting an unknown phosphacan receptor is important for PNN structure. Combining the above data, we conclude Tnr stabilizes the binding of the soluble isoform phosphacan to an unknown receptor on the neuronal surface. Scale bar, 10 μm. We quantified this using PNN node/peak analysis. C, representative images of Ptprz1 KO and Ptprz1 KO + phosphacan nodes or peaks at varying prominence levels. Yellow color dots represent nodes of highest prominence (more isolated) followed by green, blue, and black. D, representative surface intensity profile of PNNs. E, the average isolation index of PNNs represented by the mean prominence of peaks is significantly less in Ptprz1 KO + phosphacan PNNs (n = 12 PNNs, 3 cultures) compared with Ptprz1 KO cells (n = 12 PNNs, 4 cultures) indicating a decrease in the sharpness of PNN nodes or peaks with phosphacan addition in Ptprz1 KO neuronal cultures (p = 0.002, two-tailed Student’s t test, S.D. for error bars). Scale bar, 10 μm.

Phosphacan and tenascin-R cooperate to stabilize PNN components to the neuronal surface

To clarify which Ptprz1 isoform, RPTPζ or phosphacan, serves to anchor PNNs to the neuronal cell surface, we turned to our culture model system. To differentiate between isoforms, we purified soluble phosphacan from P4 mouse brains and exogenously added it to Ptprz1 WT and KO neuronal cultures. If only the receptor form RPTPζ anchored PNN structures, we would not expect the exogenous addition of phosphacan to have any affect in our PNN culture model system. Phosphacan was added to Ptprz1 cultures starting at 3 DIV. Cultures were then fixed at 9 DIV and immunostained for PNN components aggrecaen, neurocan, and Tnr (Fig. 8B).

In Ptprz1 WT cultures, aggrecan and neurocan tightly coated a population of neuronal cell bodies and proximal neurites,
whereas in Ptprz1 KO neuronal cultures, aggrecan and neurocan indiscriminately aggregated on neuronal surfaces, losing most discernable cell surface structure. Although Tnr was also spatially disrupted in Ptprz1 KO cultures, its expression on the neuronal surface was greatly diminished. After phosphacan addition to Ptprz1 KO cultures, the aggregated aggrecan and neurocan phenotype and reduced expression of Tnr in Ptprz1 KO cultures remarkably recovered to control conditions. To quantify the recovery of PNN structures in Ptprz1 KO neurons we utilized aggrecan staining and peak node/analysis as previously described. Addition of phosphacan to Ptprz1 KO cultures was sufficient to restore the spatial distribution of PNN components on the cell surface making them appear more continuous and less isolated (Fig. 8, C and D). Further, the average isolation index or mean prominence of PNN peaks was significantly lower in the Ptprz1 KO cultures with phosphacan addition as compared with Ptprz1 KO cultures alone (p = 0.002, two-tailed Student’s t test) (Fig. 8E). These data indicate that phosphacan, not RPTPζ, serves as an anchor to maintain proper spatial distribution of ECM components in vitro and, therefore, is likely the key Ptprz1 isoform that maintains the PNN lattice-like structure. Of particular interest, because of the soluble nature of phosphacan, it must bind to an unknown membrane-embedded receptor to anchor PNNs. Considering the above data, we conclude Tnr stabilizes the binding of the soluble form phosphacan to this unknown receptor on the neuronal surface and it is this binding and the interaction between both proteins that is critical for the intricate PNN lattice-like structure.

**Discussion**

Understanding and defining the molecular composition and structure of PNNs are a critical step toward unlocking their function. In the current study, we demonstrate a novel and unique role for the CSPG RPTPζ in the structure of PNNs. We show that in cooperation with Tnr, RPTPζ provides a key link to the neuronal surface, thereby generating the netlike or lattice-like structure of PNNs. These studies enabled us to create a new model of PNN structural composition that will direct more precise investigation of PNN function.

PNNs were first described over a century ago by Camillo Golgi and even though more than a hundred years of PNN research have passed, their structure and exact molecular composition has remained elusive. These structures form a subcompartment of the neural ECM but are clearly distinct from the surrounding matrix (25, 31). They are highly ordered and stable and demonstrate a unique geometry which is absent in the broader ECM (11, 43, 44). PNNs look like a mesh covering the surface of particular subsets of neurons. This meshlike appearance derives from the fact that PNN components are excluded from points of synaptic contact on the neuronal soma (45). We show here that this ordered distribution of PNNs on the neuronal surface depends on RPTPζ. In particular, there is a specific loss of the reticular structure of PNNs in Ptprz1 KO animals. Interestingly, most PNN components remain bound to the surface of the appropriate neurons in Ptprz1 KO animals but they no longer have a netlike structure. This is the first direct demonstration that RPTPζ is critically involved in PNN structure.

We noted that the altered PNNs in Ptprz1 KO animals brains seemed to significantly phenocopy disruptions previously found in Tnr KO mice (26, 37). Our results suggest that these two PNN components are a part of the same binding mechanism immobilizing PNNs and a loss of either leads to disruption and loss of staining of their components. RPTPζ is a known high-affinity ligand for Tnr (29, 30, 46). We therefore sought to better understand the biochemical nature and order of Tnr and RPTPζ binding within PNNs. Our studies here and the work of others (26) show that in Tnr-deficient brains, RPTPζ staining is reduced in PNNs, suggesting Tnr is perhaps responsible for recruiting RPTPζ to PNNs. In contrast, in primary neuronal cultures from RPTPζ knockout brains Tnr is dramatically reduced in netlike structures. Furthermore, in studies in HEK293 cells we found that RPTPζ was necessary to recruit Tnr and other PNN components to the cell surface. Therefore, overall our data suggest a cooperative mechanism by which Tnr and RPTPζ contribute to cell surface binding of PNNs.

It is of particular interest that, even though PNNs are disrupted in mice lacking RPTPζ or Tnr, the total number and distribution of PNNs in the cortex is not obviously changed. One possible explanation for this is that a key component for PNN formation, the glycosaminoglycan HA, is still expressed by these cells and this could be another nucleating molecule for the formation on PNNs. The current structural model of PNNs revolves around the lectican family of CSPGs binding to HA, which acts as backbone for PNN formation. The entire structure of HA and CSPGs is then crosslinked by Tnr. Future studies will evaluate if knocking out both Tnr and RPTPζ leads to a more pronounced phenotype to determine whether they functionally depend on each other. In our biochemical assays, the absence of RPTPζ or Tnr left PNN components susceptible to release by digesting away the HA backbone, in contrast to WT tissue that required disruption of both the HA backbone and Tnr/RPTPζ interaction. Further, the interaction between HA and CSPGs is stabilized by the protein HAPLN1 (47, 48). In mice carrying null alleles for HAPLN1, the interaction between CSPGs and HA is thought to be destabilized. PNNs in these HAPLN1 KO mice appear attenuated but the disruption is distinct from the structurally deficient PNNs of the Tnr KO mice (26, 37, 49, 50).

Our findings along with existing data on PNN structure suggest that PNN components are immobilized on the neuronal surface by two distinct interactions. One dependent on Tnr and RPTPζ being sensitive to Ca2+ ions and the other dependent on HAPLN1 and the HA backbone, susceptible to enzymatic digestion of HA. These findings enabled us to create a new and more refined model of PNN structure (Fig. 9). In this model, lectican CSPGs are bound to the HA backbone and stabilized by HAPLN1. These CSPGs are then crosslinked to RPTPζ by Tnr, which acts as an adapter protein between the two arms. Our data suggest that this interaction of the CSPGs with Tnr and RPTPζ is responsible for the meshlike appearance of PNNs and an absence of this interaction leads to the discontinuous and aggregated phenotype of PNNs seen in the Tnr KO and Ptprz1 KO mice. It should be noted that RPTPζ exists in mul-
multiple forms, splice isoforms and proteolytic cleavage products (51–53). We have also shown that PNN component binding can be partially recovered by adding the soluble form of RPTPζ (phosphacan) to dissociated neurons derived from Ptprz1 KO mice and these “rescued” neurons showed recovered binding of PNN components to the neuronal cell surface. Our data suggest that phosphacan interacts with Tnr and binds PNNs to the neuronal surface. A question therefore remains for a receptor that binds phosphacan to the neuron. RPTPζ is known to interact with several cell-surface adhesion molecules, including Ng-CAM, N-CAM, and Nr-CAM, as well as other cell surface molecules like contactin (54). It remains to be determined how soluble RPTPζ remains attached to the cell surface, as a goal of future studies. In addition we cannot formally rule out the possibility that the receptor form of RPTPζ plays a role in net structure in vivo. In fact humans do not make a secreted form of RPTPζ and therefore further studies will be needed specifically targeting the receptor form to determine its specific role in PNNs. Our work also suggests that a key nucleating event of PNN formation involves cell-surface HA, defining how HA attaches to the neuronal cell surface may provide a further key to understanding PNN specificity and structure (23, 32, 40).

Experimental procedures

Animals

Mice lacking the Ptprz1 gene (Ptprz1 KO) were generated as described previously (55) and received from Dr. Sheila Harroch (Department of Neuroscience, Institute Pasteur, Paris, France). Tenascin-R knockout (Tnr KO) adult brains (27) used for immunohistochemistry and biochemistry experiments were from Dr. Morawski’s laboratory. For neuronal cultures, in addition to Ptprz1 KO mice, timed pregnant CD-1 WT mice were purchased from Charles River Laboratories (Wilmington, MA). All experiments followed the protocols approved by the Institutional Animal Care and Use Committee of Upstate Medical University.

Antibodies

Mouse anti-phosphacan (3F8) antibody was obtained from the Developmental Studies Hybridoma Bank. Mouse anti-tenascin-R 619, sheep anti-neurocan, and goat anti-HAPLN1 was purchased from R&D Systems (Minneapolis, MN). Rabbit anti-B756, which detects amino acids 420–433 of rat brevican (56). Rabbit anti-aggrecan and mouse β-actin were both purchased from MilliporeSigma (Burlington, MA). Mouse anti-aggrecan was purchased from Bio-Rad Laboratories. Fluorescein labeled WFA was purchased from Vector Laboratories (Burlingame, CA).

Preparation of homogenates and soluble and insoluble fractions

Brain homogenates for the aggrecan release assays were derived from postnatal day 90 (PND 90) Ptprz1 WTs and Ptprz1 KOs. Tissue was homogenized in 150 mM sodium chloride and 50 mM Tris with EDTA-free protease inhibitor tablets (Roche, 1 tablet in 10 ml buffer) in a Potter-Elvehjem homogenizer. Homogenates were centrifuged at 8000 × g for 10 min at 4 °C. The supernatant was then removed, the pellet washed once and then resuspended in 1 ml buffer. A Bradford (Bio-Rad) assay was performed and protein concentrations were adjusted to 2.5 mg/ml. Samples were treated with 2 μl chondroitinase ABC (Sigma-Aldrich) per 500 μl of sample and/or 1 mM EDTA for 8 h. Samples were centrifuged again at 8000 × g for 10 min to separate soluble released fraction from insoluble pellet and prepared for Western blotting.
For analysis of overall expression of ECM components by Western blotting, PND 90 brains were homogenized in 5 volumes of 25 mM Tris (pH 7.4) containing protease inhibitor mixture, EDTA-free, and processed for analysis.

**Primary cortical cultures**

Neuronal primary cultures were prepared as described previously (23). Briefly, cortices of embryonic day (E) 16 CD-1 WT or Ptprz1 KO embryos were removed and digested in 0.25% trypsin-EDTA (Thermo Fisher Scientific). Mixed cells were filtered and suspended in Neurobasal medium with 3% B27, 1× GlutaMAX and 1× penicillin-streptomycin (Thermo Fisher Scientific). Cells were then plated at a density of 2.1 × 10⁶ on coverslips (500 µl per well) precoated with poly-d-lysine (50 µg/ml) and laminin (5 µg/ml) (Sigma-Aldrich) in a 24-well dish. To remove glia, cells were treated with 5 µM cytosine arabinoside (AraC, Sigma-Aldrich) at 1 day in vitro (DIV). The medium was then changed at 3 DIV to remove AraC, and given a half change at 6 DIV. Cells were maintained at 37 °C 5% CO₂ until fixation.

Phosphacan was purified by anion exchange chromatography as described previously (57). Briefly, the soluble fraction, from PND 4 CD-1 mouse brain, was filtered using a PVDF 0.22 µM filter, brought to a 0.5 M NaCl concentration, and run through a 1 ml HiTrap-Q HP column using a peristaltic pump connected to an Amersham Biosciences Pharmacia RediFrac fraction collector (GE Healthcare Life Sciences). Sample was eluted over a continuous gradient of 0.5 M NaCl to 2.0 M NaCl over 10 column volumes and collected as 250 µl fractions. Phosphacan-rich fractions, identified by dot blot analysis, were pooled and concentrated using 100,000 MWCO Concentrators (AmiconUltra, EMD Millipore). Approximately 250 ng of purified phosphacan was added to Ptprz1 KO cultures after the first medium change at 3 DIV and 125 ng was added after the half-medium change at 6 DIV and analyzed at 9 DIV. When noted, coverslips were treated with 10 µl ChABC for 30 min and/or 2.5 mm EGTA for 15 min. Coverslips were fixed and subsequently processed for immunocytochemistry.

**Immunocytochemistry and immunohistochemistry**

Primary cortical cultures plated on coverslips were fixed at 9 DIV in cold 4% phosphate-buffered paraformaldehyde (PFA) with 0.01% glutaraldehyde, pH 7.4. Cells were then blocked in screening medium (DMEM, 5% FBS, 0.2% sodium azide) for 1 h, before adding primary antibodies overnight at 4 °C. The following day, Alexa Fluor−conjugated secondary antibodies (Thermo Fisher Scientific) in screening medium were added to the cells for 2 h before mounting the coverslips with ProLong Antifade Kit (Thermo Fisher Scientific). Cell nuclei were visualized with Hoechst solution (Thermo Fisher Scientific) diluted in 1× PBS. For immunohistochemistry on tissue sections, PND 90 Ptprz1 and Tnr (all genotypes) mice were transcardially perfused with cold PBS (Thermo Fisher Scientific) prior to fixation with 4% PFA. Brains were postfixed overnight in 4% PFA before changing to a 30% sucrose solution diluted in phosphate buffer with 0.2% sodium azide. Using a cryostat, brains were cut as free-floating sections at 40 µm and placed in phosphate buffer with 0.2% sodium azide. Sections were blocked 1 h at room temperature and then stained in either 5% milk in TBST with 1% Triton X-100 (mouse anti-tenascin-R 619, sheep anti-nercan, rabbit anti-breivican) or screening medium with 1% Triton X-100 (WFA, mouse anti-aggreca, goat anti-HAPLN1, and mouse anti-phosphacan). Tissue sections were additionally stained with Hoechst solution to visualize nuclei before being mounted on glass slides. Both cells and tissue were imaged using an epifluorescent Zeiss Imager.A2 with Nikon Elements software package. Final images were gathered and formatted using ImageJ software (58) and assembled into figures using Adobe Illustrator CC 2019.

**SDS-PAGE and Western blotting**

Protein concentrations were determined by Bradford assay before gel electrophoresis. For detection of CSPGs, brain lysates were treated with 2 µl ChABC (Millipore Sigma, C3667, 0.1mU/µl) for 8 h at 37 °C to remove chondroitinase sulfate side chains and allow proper gel migration. SDS-polyacrylamide gels, used at either 4–12% or 6–15% gradient, were transferred to 0.45 µm nitrocellulose membranes. Western blotting was conducted as described previously (59). Briefly, blots were placed in blocking buffer composed of 5% milk in low-salt TBST and then incubated in primary antibody overnight. Blots were then incubated in HRP-conjugated secondary antibodies (The Jackson Laboratory, Bar Harbor, ME) and exposed using SuperSignal West Pico Chemiluminescent Substrate or SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific). Blots were imaged using ChemiDoc MP system (Bio-Rad) or using Premium X-ray film (Phenix Research Products, Candler, NC).

**Quantification and statistical analyses**

The binary gap analysis was used to quantify regions devoid of PNN. For analysis, high magnification z-stack images (0.25 µM steps, 63× magnification) of PNNs, visualized with WFA, were taken throughout the PND 90 adult somatosensory cortex (Bregma, −2.46 mm) of Ptprz1 KO strain mice. To better visualize PNN surface structure, nets were flattened using the Z-project, max intensity function on ImageJ (58). Once flattened, a fixed region excluding the PNN periphery (~25 µm²) was cropped from the estimated center of the PNN and thresholded to obtain a binary (black and white) image to analyze the PNN surface. The black/white pixel count ratio for each PNN was determined using the histogram function and averaged for each genotype.

PNN peak or node analysis was used to quantitatively describe the PNN aggregation seen on the surface of neurons in Tnr KO and Ptprz1 KO mice. Z-projected images of the PNN were processed using the local maxima function of ImageJ to identify peaks (nodes) of intense PNN staining. Once the nodes were identified, an ad hoc algorithm was used to measure the average distance between those nodes and the difference in intensity between the nodes and their surrounding space on the cell surface (node prominence) The number of unique nodes and their mean prominence was plotted for each genotype.

The quantification of ECM components in Ptprz1 KO was assessed through immunohistochemistry (IHC) and Western blot analysis. For IHC, adult coronal sections approximately at Bregma −2.46 mm were stained to detect the PNN-specific...
RPTPζ/phosphacan is critical for PNNs

components aggrecan, WFA (detects CS chains, dependent on aggrecan expression) and HAPLN1, and the PNN-associated components brevican, neurocan, and tenascin-R (Tnr). For quantification of specific net components, 10× large stitch images, processed by the Nikon Elements software, were taken of the cortex of Ptprz1 KO and WT mice. The pixel intensity of each specific PNN component was determined by taking a region of interest of the cortex and using the measure function of ImageJ. To quantify nonspecific PNN markers (brevican, neurocan, and Tnr), a region of interest and intensity measurement of ImageJ. To quantify nonspecific PNN markers (brevican, neurocan, and Tnr), a region of interest and intensity measurement was taken of a sample set of individual PNNs (average of 25 PNNs per animal) throughout the adult cortices (images taken at 20×). PNN pixel intensity was then averaged for each genotype and significance determined using an unpaired Student’s t test, p < 0.05. To produce bar graphs, data were normalized and scaled.

Western blot analysis was used to further quantify the PNN-specific components aggrecan and HAPLN1. Cortices were specifically taken from Ptprz1 KO and WT mice, homogenized, separated on a 4–12% SDS-polyacrylamide gel and transferred to nitrocellulose for blotting. Western blots for aggrecan and HAPLN1 expression were imaged using ChemiDoc MP system (Bio-Rad) and analyzed in ImageJ. Expression was determined by taking the average ratio of PNN-specific component intensity to β-actin intensity for each genotype. Differences were found significant at p < 0.05 (unpaired Student’s t test or analysis of variance (ANOVA) with Tukey’s post hoc analyses as appropriate) using GraphPad Prism 7/8 or RStudio statistical software.

Author contributions—G. J. E. and A. S. data curation; G. J. E., A. S., M. S. V., and R. T. M. formal analysis; G. J. E., A. S., and R. T. M. investigation; G. J. E. and A. S. visualization; G. J. E., A. S., and M. S. V. methodology; G. J. E. and A. S. writing—original draft; M. M., M. S. V., and R. T. M. conceptualization; M. M. and R. T. M. resources; M. M. and R. T. M. funding acquisition; M. M., M. S. V., and R. T. M. writing—review and editing; R. T. M. supervision; R. T. M. project administration.

Acknowledgment—We thank Dr. Mandy Sonntag for helping with preparation of the tissue from the tenascin-R knockout mice.

References
1. Pizzorusso, T., Medini, P., Berardi, N., Chierzi, S., Fawcett, J. W., and Maffeï, L. (2002) Reactivation of ocular dominance plasticity in the adult visual cortex. *Science* **298**, 1248–1251 CrossRef Medline
2. Gogolla, N., Caroni, P., Lüthi, A., and Herry, C. (2009) Perineuronal nets protect fear memories from erasure. *Science* **325**, 1258–1261 CrossRef Medline
3. Romberg, C., Yang, S., Melani, R., Andrews, M. R., Horner, A. E., Spillantini, M. G., Bussey, T. J., Fawcett, J. W., Pizzorusso, T., and Saksida, L. M. (2013) Depletion of perineuronal nets enhances recognition memory and long-term depression in the perirhinal cortex. *J. Neurosci.* **33**, 7057–7065 CrossRef Medline
4. Yang, S., Cacquevel, M., Saksida, L. M., Bussey, T. J., Schneider, B. L., Aebischer, P., Melani, R., Pizzorusso, T., Fawcett, J. W., and Spillantini, M. G. (2015) Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology. *Exp. Neurol.* **265**, 48–58 CrossRef Medline
5. Pizzorusso, H., Woo, T.-U. W., Lim, M. P., Lange, N., and Berretta, S. (2010) Extracellular matrix-glial abnormalities in the amygdala and ento-rhinal cortex of subjects diagnosed with schizophrenia. *Arch. Gen. Psychiatry* **67**, 155–166 CrossRef Medline
6. Pizzorusso, H., Markota, M., Jaquet, F., Ghosh, D., Wallin, A., Santos, A., Caterson, B., and Berretta, S. (2015) Aggrecan and chondroitin-6-sulfate abnormalities in schizophrenia and bipolar disorder: A postmortem study on the amygdala. *Transl. Psychiatry* **5**, e496 CrossRef Medline
7. Mauney, S. A., Athanas, K. M., Pizzopuso, H., Shaskan, N., Passeri, E., Berretta, S., and Woo, T.-U. W. (2013) Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. *Biol. Psychiatry* **74**, 427–435 CrossRef Medline
8. Viapiano, M. S., and Matthews, R. T. (2006) From barriers to bridges: Chondroitin sulfate proteoglycans in neuropathology. *Trends Mol. Med.* **12**, 488–496 CrossRef Medline
9. Brückner, G., Brauer, K., Härtig, W., Wolff, J. R., Rickmann, M. J., Derouiche, A., Delpech, B., Girard, N., Oertel, W. H., and Reichenbach, A. (1993) Perineuronal nets provide a polyanionic, glia-associated form of microenvironment around certain neurons in many parts of the rat brain. *GLIA* **8**, 181–200 CrossRef Medline
10. Celio, M. R., Spreafico, R., De Biasi, S., and Vitale-Neuroglial, L. (1998) Perineuronal nets: Past and present. *Trends Neurosci.* **21**, 510–515 CrossRef Medline
11. Lander, C., Kind, P., Maleski, M., and Hochfeld, S. (1997) A family of activity-dependent neuronal cell-surface chondroitin sulfate proteoglycans in cat visual cortex. *J. Neurosci.* **17**, 1928–1939 CrossRef Medline
12. Hochfeld, S., Kalb, R. G., Zaremba, S., and Fryer, H. (1990) Expression of neural proteoglycans correlates with the acquisition of mature neuronal properties in the mammalian brain. In *Cold Spring Harb. Symp. Quant. Biol.* **55**, 505–514 CrossRef Medline
13. McKeon, R. J., Schreiber, R. C., Rudge, J. S., and Silver, J. (1991) Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. *J. Neurosci.* **11**, 3398–3411 CrossRef Medline
14. Niederöst, B. P., Zimmermann, D. R., Schwab, M. E., and Bandi, C. E. (1999) Bovine CNS myelin contains neurite growth-inhibitory activity associated with chondroitin sulfate proteoglycans. *J. Neurosci.* **19**, 8979–8989 CrossRef Medline
15. Bradbury, E. J., Moon, L. D., Popat, R. J., King, V. R., Bennett, G. S., Patel, P. N., Fawcett, J. W., and McMahon, S. B. (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature* **416**, 636–640 CrossRef Medline
16. McRae, P. A., Rocco, M. M., Kelly, G., Brumberg, J. C., and Matthews, R. T. (2007) Sensory deafferentation alters aggrecan and perineuronal net expression in the mouse barrel cortex. *J. Neurosci.* **27**, 5405–5413 CrossRef Medline
17. Balmer, T. S., Carels, V. M., Frisch, J. L., and Nick, T. A. (2009) Modulation of perineuronal nets and parvalbumin with developmental song learning. *J. Neurosci.* **29**, 12878–12885 CrossRef Medline
18. Pizzorusso, T., Medini, P., Landi, S., Baldini, S., Berardi, N., and Maffeï, L. (2006) Structural and functional recovery from early monocular deprivation in adult rats. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 8517–8522 CrossRef Medline
19. Xue, Y.-X., Xue, L.-F., Liu, J.-F., He, J., Deng, J.-H., Sun, S.-C., Han, H.-B., Luo, Y.-X., Xu, L.-Z., Wu, P., and Lu, L. (2014) Depletion of perineuronal nets in the amygdala to enhance the erasure of drug memories. *J. Neurosci.* **34**, 6647–6658 CrossRef Medline
20. Végh, M. I., Heldring, C. M., Kanphuis, W., Hijazi, S., Timmerman, A. J., Li, K. W., van Nierop, P., Manwelder, H. D., Hol, E. M., Smit, A. B., and van Kesteren, R. E. (2014) Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer’s disease. *Acta Neuropathol. Commun.* **2**, 76 CrossRef Medline
21. Slaker, M., Churchill, L., Todd, R. P., Blacktop, J. M., Zuloaga, D. G., Raber, J., Darling, R. A., Brown, T. E., and Sorg, B. A. (2015) Removal of perineuronal nets in the amygdala to enhance the erasure of drug memories. *Biol. Psychiatry.* **74**, e496 CrossRef Medline
22. Lee, H., Leamy, C. A., and Sawatari, A. (2012) Perineuronal nets play a role in regulating striatal function in the mouse. *PLoS One* **7**, e32747 CrossRef Medline
23. Giamanco, K. A., Morawski, M., and Matthews, R. T. (2010) Perineuronal net formation and structure in aggrecan knockout mice. *Neuroscience* 170, 1314–1327 CrossRef Medline

24. Rowlands, D., Lensjø, K. K., Dinh, T., Yang, S., Andrews, M. R., Hafting, T., Fynh, M., Favcett, J. W., and Dick, G. (2018) Aggreccan directs extracellular matrix-mediated neuronal plasticity. *J. Neurosci.* 38, 10102–10113 CrossRef Medline

25. Deepa, S. S., Carulli, D., Galtrey, C., Rhodes, K., Fukuda, J., Mikami, T., Sugahara, K., and Favcett, J. W. (2006) Composition of perineuronal extracellular matrix in rat brain: A different disaccharide composition for the net-associated proteoglycans. *J. Biol. Chem.* 281, 17789–17800 CrossRef Medline

26. Brückner, G., Grosche, J., Schmidt, S., Härting, W., Margolis, R. U., Delpech, B., Seidenbecher, C. I., Czarnia, R., and Schachner, M. (2000) Postnatal development of perineuronal nets in wild-type mice and in a mutant deficient in tenascin-R. *J. Comp. Neurol.* 428, 616–629 CrossRef Medline

27. Weber, P., Bartsch, U., Rasband, M. N., Czaniera, R., Lang, Y., Bluthmann, H., Margolis, R. U., Levinson, S. R., Shrager, P., Montag, D., and Schachner, M. (1999) Mice deficient for tenascin-R display alterations of the extracellular matrix and decreased axonal conduction velocities in the CNS. *J. Neurosci.* 19, 4245–4262 CrossRef Medline

28. Barnea, G., Grumet, M., Milev, P., Silvennoinen, O., Levy, J. B., Sap, J., and Schlessinger, J. (1994) Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin. *J. Biol. Chem.* 269, 14349–14352 Medline

29. Xiao, Z., Bartsch, U., Margolis, K., Montag, D., Schachner, M., and Zu, C. (1997) Isolation of a tenascin-R binding protein from mouse brain membranes. A phosphacan-related chondroitin sulfate proteoglycan. *J. Biol. Chem.* 272, 52902–52101 CrossRef Medline

30. Milev, P., Chiba, A., Häring, M., Rauvala, H., Schachner, M., Ranscht, B., Margolis, R. K., and Margolis, R. U. (1998) High affinity binding and overlapping localization of neurocan and phosphacan protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphiregulin, and the heparin-binding growth-associated molecule. *J. Biol. Chem.* 273, 6998–7005 CrossRef Medline

31. Grumet, M., Milev, P., Sakurai, T., Karthikeyan, L., Bourdon, M., Margolis, R. K., and Margolis, R. U. (1994) Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan protein-tyrosine phosphatase-zeta/beta with tenascin-R, amphiregulin, and the heparin-binding growth-associated molecule. *J. Biol. Chem.* 269, 12142–12146 Medline

32. Haunso, A., Ibrahim, M., Bartsch, U., Lettiembre, M., Celio, M. R., and Menoud, P. (2000) Morphology of perineuronal nets in tenascin-R and parvalbumin single and double knockout mice. *Brain Res. 864*, 142–145 CrossRef Medline

33. Morawski, M., Dityatev, A., Hartlage-Ruebsamen, M., Blosa, M., Holzer, M., Meyer, H., Krug, M., Seidenbecher, C. I., Boeckers, T. M., Rauch, U., Bettner, R., Gundelfinger, E. D., and Fässler, R. (2001) Neurocan is dispensable for brain development. *Mol. Cell Biol.* 21, 5970–5978 CrossRef Medline

34. Brakebusch, C., Seidenbecher, C. I., Asztely, F., Rauch, U., Matthies, H., Kreutz, M. R., Montag, D., Gundelfinger, E. D., and Fa, R. (2002) Brevican-deficient mice display impaired hippocampal CA1 long-term potentiation but show no obvious deficits in learning and memory. *Mol. Cell. Biol.* 22, 7417–7427 CrossRef Medline

35. Suttkus, A., Rohn, S., Weigel, S., Glöckner, P., Arendt, T., and Morawski, M. (2014) Aggreccan, link protein and tenasin-R are essential components of the perineuronal net to protect neurons against iron-induced oxidative stress. *Cell Death Dis.* 5, e1119 CrossRef Medline

36. Morawski, M., and Sonntag, M. (2018) Perineuronal nets in the superior olivary complex: Development, function, and plasticity. in *The Oxford Handbook of the Auditory Brainstem* (Kandler, K., ed.), pp. 1–28, Oxford University Press, New York, New York CrossRef Medline

37. Härting, W., Derouiche, A., Welt, K., Brauer, K., Grosje, J., Máder, M., Reichenbach, A., and Brückner, G. (1999) Cortical neurons immunoreactive for the potassium channel Kv4.1b subunit are predominantly surrounded by perineuronal nets presumed as a buffering system for cations. *Brain Res.* 842, 15–29 CrossRef Medline

38. Arntz, N., Kuzznetsova, S., Lipachev, N., Shakhbudinov, N., Melnikova, A., Mavlikeyev, M., Uvarov, P., Baltina, T. V., Rauvala, H., Osin, Y. N., Kiyasov, A. P., and Paveliev, M. (2016) Spatial patterns and cell surface clusters in perineuronal nets. *Brain Res.* 1648, 214–223 CrossRef Medline

39. Hoffkeld, S., and McKay, R. D. (1983) A surface antigen expressed by a subset of neurons in the vertebrate central nervous system. *Proc. Natl. Acad. Sci. USA.* 80, 5758–5761 CrossRef Medline

40. Peles, E., Schlessinger, J., and Grumet, M. (1998) Multi-ligand interactions with receptor-like protein tyrosine phosphatase β: Implications for intercellular signaling. *Trends Biochem. Sci.* 23, 121–124 CrossRef Medline

41. Tsirfilna, E., Ananyeva, N. M., Hastings, G., and Liu, G. (1999) Identification and characterization of three cDNAs that encode putative novel hyaluronan-binding proteins, including an endothelial cell-specific hyaluronan receptor. *Ann. J. Pathol.* 155, 1625–1633 CrossRef Medline

42. Monslow, J., Williams, J. D., Norton, N., Guy, C. A., Price, I. K., Coleman, S. L., Williams, N. M., Backlund, P. R. S., Spencer, A. P., Topley, N., Davies, M., and Bowen, T. (2003) The human hyaluronan synthase genes: Genomic structures, proximal promoters and polymorphic microsatellite markers. *Int. J. Biochem. Cell Biol.* 35, 1272–1283 CrossRef Medline

43. Bekku, Y., Su, W., Hirakawa, S., Fa, R., Ohtsuka, A., Kang, J. S., Sanders, I., Murakami, T., Ninomiya, Y., and Oohashi, T. (2003) Molecular cloning of Bral2, a novel brain-specific link protein, and immunohistochemical co-localization with brevican in perineuronal nets. *Mol. Cell Neurosci.* 24, 148–159 CrossRef Medline

44. Carulli, D., Pizzorusso, T., Kwok, J. C. F., Putignano, E., Poli, A., Forostyak, S., Andrews, M. R., Deepa, S. S., Glant, T. T., and Fawcett, J. W. (2010) Animals lacking link protein have attenuated perineuronal nets and persistent plasticity. *Brain 133*, 2331–2347 CrossRef Medline

45. Garwood, J., Schnädelbach, O., Clement, A., Schütte, K., Bach, A., and Faisnser, A. (1999) DSD-1-proteoglycan is the mouse homolog of phosphacan and displays opposing effects on neurite outgrowth dependent on neuronal lineage. *J. Neurosci.* 19, 3888–3899 CrossRef Medline

46. Garwood, J., Heck, N., Reichardt, F., and Faisnser, A. (2003) Phosphacan short isoform, a novel non-proteoglycan variant of phosphacan/receptor protein tyrosine phosphatase-β, interacts with neural receptors and promotes neurite outgrowth. *J. Biol. Chem.* 278, 24164–24173 CrossRef Medline

47. Chow, J. P. H., Fujikawa, A., Shimizu, H., Suzuki, R., and Noda, M. (2008) Metalloproteinase- and γ-secretase-mediated cleavage of protein-tyrosine phosphatase receptor type Z. *J. Biol. Chem.* 283, 30879–30889 CrossRef Medline
RPTPζ/phosphacan is critical for PNNs

54. Lamprianou, S., Chatzopoulou, E., Thomas, J.-L., Bouyain, S., and Harroch, S. (2011) A complex between contactin-1 and the protein tyrosine phosphatase PTPZ controls the development of oligodendrocyte precursor cells. Proc. Natl. Acad. Sci. U.S.A. 108, 17498–17503 CrossRef Medline

55. Harroch, S., Palmeri, M., Rosenbluth, J., Custer, A., Okigaki, M., Shrager, P., Blum, M., Buxbaum, J. D., and Schlessinger, J. (2000) No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase β. Mol. Cell Biol. 20, 7706–7715 CrossRef Medline

56. Blosa, M., Bursch, C., Weigel, S., Holzer, M., Jäger, C., Janke, C., Matthews, R. T., Arendt, T., and Morawski, M. (2016) Reorganization of synaptic connections and perineuronal nets in the deep cerebellar nuclei of Purkinje cell degeneration mutant mice. Neural Plast. 2016, 2828536 CrossRef Medline

57. Dwyer, C. A., Katoh, T., Tiemeyer, M., and Matthews, R. T. (2015) Neurons and glia modify receptor protein-tyrosine phosphatase ζ (RPTPζ)/phosphacan with cell-specific O-mannosyl glycans in the developing brain. J. Biol. Chem. 290, 10256–10273 CrossRef Medline

58. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Petzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J.-Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., and Cardona, A. (2012) Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676–682 CrossRef Medline

59. Viapiano, M. S., Matthews, R. T., and Hockfield, S. (2003) A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma. J. Biol. Chem. 278, 33239–33247 CrossRef Medline